219 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
IONS Ionis Pharmaceuticals, Inc. $48.21 $6.62B N/A
Article Searches
Here's Why Ionis Pharmaceuticals Rose 12.9% in September https://www.fool.com/investing/2018/10/11/heres-why-ionis-pharmaceuticals-rose-129-in-septem.aspx?source=iedfolrf0000001 Oct 11, 2018 - The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
After-hours buzz: AMD, AKCA, IONS & more https://www.cnbc.com/2018/08/27/stocks-making-the-biggest-moves-after-hours-amd-akca-ions--more.html Aug 27, 2018 - See which stocks are posting big moves after the bell.
Why Biogen's Stock Ripped Higher in July https://www.fool.com/investing/2018/08/11/why-biogens-stock-ripped-higher-in-july.aspx?source=iedfolrf0000001 Aug 11, 2018 - Biogen's stock got a boost from two material events last month.
Biogen Posts Solid Earnings as the Biotech Waits for Clinical Trial Data https://www.fool.com/investing/2018/07/25/biogen-posts-solid-earnings-as-the-biotech-waits-f.aspx?source=iedfolrf0000001 Jul 25, 2018 - Looking for the next Spinraza.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up http://www.zacks.com/stock/news/313015/biogen-biib-q2-earnings-sales-beat-estimates-shares-up?cid=CS-ZC-FT-313015 Jul 24, 2018 - Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates http://www.zacks.com/stock/news/311982/biotech-stock-roundup-amgn-resubmits-evenity-bla-advaxis-soars-regulatory-updates?cid=CS-ZC-FT-311982 Jul 18, 2018 - It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Better Buy: Biogen Inc. vs. Amgen https://www.fool.com/investing/2018/07/15/better-buy-biogen-inc-vs-amgen.aspx?source=iedfolrf0000001 Jul 15, 2018 - Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearly has an easier path toward value creation.
Is Ionis Pharmaceuticals, Inc. a Buy? https://www.fool.com/investing/2018/07/12/is-ionis-pharmaceuticals-inc-a-buy.aspx?source=iedfolrf0000001 Jul 12, 2018 - One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer http://www.zacks.com/stock/news/311215/bristol-myers-combo-drugs-get-fda-nod-for-colorectal-cancer?cid=CS-ZC-FT-311215 Jul 12, 2018 - Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8% http://www.zacks.com/stock/news/310998/summit-therapeutics-smmt-catches-eye-stock-jumps-88?cid=CS-ZC-FT-310998 Jul 11, 2018 - Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Pages: 12345678910...22

<<<Page 5>